Prescription medicine
Ziprasidone Brand names: Geodon
Ziprasidone (Geodon) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 23 generic labelers, and pharmacies paid $0.269 per ziprasidone HCl 20 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.); the NDA 20825 record on Drugs@FDA; every ziprasidone label on DailyMed.
Highlights of the record
FDA label of July 20, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone capsules are not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone capsules are not approved for the treatment of patients with dementia-related psychosis.
Used for
From the label: indications and usageZiprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder.
Forms and strengths
- 20 mg
- 40 mg
- 60 mg
- 80 mg
- 20 mg/ml
Capsule; injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- February 5, 2001 Geodon, Viatris; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 12 first March 2, 2012; 10 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 25 of which 23 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.269 per capsule Ziprasidone HCl 20 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2023 1 Class I among all firms' recalls; latest May 31, 2023
- FAERS reports
- 6,148 through July 30, 2026
What is ziprasidone used for?
From the label: indications and usageZiprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions ( 5.3 ) ]. […]
Conditions named in the indications of ziprasidone's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Atypical Antipsychotic.
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
Is there a generic for ziprasidone (Geodon)?
The FDA approved the first generic ziprasidone on March 2, 2012. 12 generic applications are approved; 10 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists ziprasidone from 23 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2001 earliest approval on file
- 2012 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ziprasidone (Geodon)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.269 per Ziprasidone HCl 20 mg capsule, down 13% from $0.309 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ziprasidone HCl 20 mg capsule (generic)
- Geodon 80 mg capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ziprasidone 20 mg/mL vial | Generic | $21.81 per vial many times the lowest per-tablet cost; NADAC records the price, not why | n/a | +22% |
| Ziprasidone HCl 20 mg capsule | Generic | $0.269 per capsule | $8.08 | -13% |
| Ziprasidone HCl 40 mg capsule | Generic | $0.272 per capsule | $8.17 | +4% |
| Ziprasidone HCl 60 mg capsule | Generic | $0.314 per capsule | $9.42 | -3% |
| Ziprasidone HCl 80 mg capsule | Generic | $0.316 per capsule | $9.47 | -14% |
| Geodon 80 mg capsule | Brand | $31.11 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $933.24 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has ziprasidone been recalled?
The FDA's Enforcement Report lists 1 recall naming ziprasidone since 2023: 1 Class I (the most serious), 0 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 31, 2023 | Class I | The Harvard Drug Group LLC dba Major Pharmaceuticals and … | Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the ziprasidone label say about other medicines?
The ziprasidone label names 35 other medicines in its interaction, contraindication or warning sections. The labels of 14 other medicines name ziprasidone. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aripiprazole | warnings and precautions | Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. |
| Arsenic trioxide | contraindications | … chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. … |
| Benztropine | drug interactions | Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. |
| Buspirone | drug interactions | Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort [see Contraindications ( 4.3 ), Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6.2 )]. |
| Carbamazepine | drug interactions | Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. |
| Chlorpromazine | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron … |
| Cimetidine | drug interactions | Cimetidine Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics. |
| Dextromethorphan | drug interactions | There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio. |
| Dofetilide | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron … |
| Droperidol | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron … |
| Fentanyl | warnings and precautions | The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. … |
| Gatifloxacin | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron … |
| Haloperidol | warnings and precautions | The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. |
| Ketoconazole | drug interactions | Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and C max of ziprasidone by about 35 to 40%. |
Every other medicine the ziprasidone label names
| Medicine named | Section | What the label says |
|---|---|---|
| Levodopa | drug interactions | Ziprasidone may antagonize the effects of levodopa and dopamine agonists. |
| Levonorgestrel | drug interactions | Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). |
| Linezolid | contraindications | Inhibitors (MAOIs) Ziprasidone is contraindicated in patients taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk … |
| Lithium | drug interactions | Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and … |
| Lorazepam | drug interactions | … significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. |
| Mefloquine | contraindications | … pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. … |
| Meperidine | warnings and precautions | … (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. … |
| Methadone | warnings and precautions | … triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. … |
| Methylene blue | contraindications | … of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.4 ), Drug Interaction ( 7.3 )]. |
| Moxifloxacin | contraindications | … chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or … |
| Olanzapine | warnings and precautions | … 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. |
| Pimozide | contraindications | … anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl … |
| Progesterone | drug interactions | In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. |
| Propranolol | drug interactions | … clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. |
| Quetiapine | warnings and precautions | … greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. |
| Quinidine | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide … |
| Risperidone | warnings and precautions | The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but … |
| Sotalol | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide … |
| Tacrolimus | contraindications | … arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect … |
| Thioridazine | contraindications | Therefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide … |
| Tramadol | warnings and precautions | … inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. … |
Other labels that name ziprasidone
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
What do FAERS reports show for ziprasidone?
The FDA Adverse Event Reporting System holds 6,148 reports that list ziprasidone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 931 are coded as a death and 2,159 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as ziprasidone?
16 other medicines are given the same way (oral) and in the same FDA class as ziprasidone or labeled mainly for the same use (bipolar disorder), the same class first. Bipolar disorder lists all 17 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Quetiapine | Bipolar disorder, Schizophrenia | 50 labelers | $0.127 per tablet 300 mg tablet | No current entry |
| Aripiprazole | Bipolar disorder, Schizophrenia | 47 labelers | $0.110 per tablet 5 mg tablet | No current entry |
| Olanzapine | Bipolar disorder, Schizophrenia | 33 labelers | $0.147 per tablet 20 mg tablet | No current entry |
| Risperidone | Bipolar disorder, Schizophrenia | 35 labelers | $0.0368 per tablet 0.25 mg tablet | No current entry |
| Lurasidone | Bipolar disorder, Schizophrenia | 29 labelers | $0.142 per tablet 20 mg tablet | No current entry |
| Paliperidone | Schizophrenia | 18 labelers | $0.972 per tablet 3 mg tablet | No current entry |
| Clozapine | Schizophrenia | 11 labelers | $0.610 per tablet 100 mg tablet | No current entry |
| Iloperidone | Bipolar disorder, Schizophrenia | 1 labeler | $60.01 per tablet 12 mg tablet | No current entry |
Every medicine labeled for the same conditions as ziprasidone
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does ziprasidone compare with medicines for the same use?
3 side-by-side pages set ziprasidone beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to ziprasidone
- 16 medicines for the same use
- Other atypical antipsychotics
- the pharmacologic class, with prices and generics
- Ziprasidone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other